November 19, 2020
TissueTech Announces Engagement of Pro-ficiency Virtual Study Trainer™ for Clinical Trials
Miami, FL – November 19, 2020 – TissueTech, Inc., an emerging biotechnology company and pioneer in the clinical application of cryopreserved amniotic membrane and umbilical cord birth tissue allografts, announced today the engagement of Pro-ficiency Virtual Study Trainer™ to facilitate remote study protocol training for TissueTech’s clinical trial investigators and their clinical research teams.
TissueTech has been quick to integrate proven technologies to meet the rapidly changing clinical trial industry landscape during the pandemic and maintain compliance with FDA guidance. Even in the best of times, effectual training on complicated protocols is a challenge. Ensuring investigator compliance with regulatory guidelines is paramount to building a foundation for any successful trial. Recognizing the costs and risks associated with face-to-face training and needing a proven solution, TissueTech selected Pro-ficiency to ensure success in their late-breaking Diabetic Foot Ulcer study in this new operating environment.
“As we were evaluating ways to leverage innovative technologies to solve some of the challenges faced with launching late-breaking trials amidst the onset of the pandemic, investigator training was a specific area of focus and concern,” said Tommy Lee, Vice President of Clinical Operations at TissueTech. “Pro-ficiency uniquely stood out from the available options providing critical measures of protocol understanding through simulation training. This method was very attractive as it optimized the investigator’s ability to learn through immersive and engaging real-world scenarios designed to test their understanding of the trial’s protocol.”
Pro-ficiency’s Virtual Study Trainer ™ uses the most advanced Remote Site Performance Management technology in the industry. Offering both Virtual IM™ and Virtual SIV™, Pro-ficiency aids in avoiding the cost and complexity of travel and scheduling and training every investigator and site staff to the highest performance standards possible. Remote learning at Pro-ficiency utilizes simulation-training and remote site performance management, ensuring virtual training is just as effective as the face-to-face alternative.
Pro-ficiency CEO David Hadden says: “We are proud to be working alongside TissueTech on a meaningful, innovative project targeting an unmet medical need in diabetic patients living with complex diabetic foot ulcers and in need of advanced wound management.”
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 360 peer-reviewed studies supporting its platform technology. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at https://biotissue.com/.